Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation

Clinical Cancer Research

Volumn 10, Issue 18 I, 2004, Pages 6066-6071

  Camphausen, Kevin ^a   Scott, Tamalee ^a   Sproull, Mary ^a   Tofilon, Philip J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CELL LYSATE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HISTONE HYPERACETYLATION; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; RADIOSENSITIVITY; SCID MOUSE; TUMOR CELL; TUMOR XENOGRAFT;

ACETYLATION; ANIMALS; BENZAMIDES; BIOPSY; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE DEACETYLASES; HISTONES; HUMANS; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PYRIDINES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 4644259264     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0537     Document Type: Article

References (20)

1. Johnstone R. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;4:287-99.
2. Biade S, Stobbe C, Boyd J, Chapman J. Chemical agents that promote chromatin compaction radiosensitize tumor cells. Int J Radiat Biol 2001;77:1033-42.
3. Riggs M, Whittaker R, Neumann J, Ingram V. n-Butyrate causes histone modification in HeLa and Friend erythroleulaemia cells. Nature (Lond.) 1977;268:462-4.
4. Arundel C, Glicksman A, Leith J. Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB). Radiât Res 1985;104:443-8.
5. Novogrodsky A, Dvir A, Ravid A, et al. Effect of polar organic compounds on leukemic cells. Cancer (Phila.) 1983;51:9-14.
6. Miller A, Kurschel E, Osieka R, Schmidt C. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur Cancer Clin Oncol 1987;23:1283-7.
7. Perrine S, Ginder G, Faller D, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993;328:81-6.
8. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1982 5;42(2):65-82.
9. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem 2001;8:1505-11.
10. Blagosklonny M, Robey R, Sackett D, et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002;1:937-41.
11. Saito A, Yamashita T, Manko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999;96:4592-7.
12. Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of gamma-H2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004;64:316-21.
13. O'Reilly M, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by Lewis lung carcinoma. Cell 1994;79:315-28.
14. Jaboin J, Wild J, Hamidi H, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002;62:6108-15.
15. Gelmon K, Eisenhauer E, Harris A, Ratain M, Workman P. Anti-cancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (Bethesda) 1999;91:1281-7.
16. Korn E, Arbuck S, Pluda J, Simon R, Kaplan R, Christian M. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001;19:265-72.
17. Rosato R, Almenara J, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res 2003;63:3637-45.
18. Fournel M, Trachy-Bourget MC, Van FT, et al. Sulfonamide anilides, a novel class if histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 2002;62:4325-30.
19. Kim M, Blake M, BAek J, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003;63:7291-300.
20. Kelly W, O'Conner O, Marks P. Histone deacetylase inhibitors: from targets to clinical trials. Expert Opin Investig Drugs 2002;11:1695-713.